Senior Scientist, Drug Substance
MBX Biosciences
This listing was originally posted on MBX Biosciences's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moPosition Summary
The Senior Scientist, Drug Substance will drive the development and optimization of scalable, efficient, and sustainable synthetic routes for MBX’s peptide drug substances and intermediates. In this role, you’ll support late‑stage development activities, contribute to QbD initiatives, and help define control strategies aligned with global regulatory expectations.
You will provide technical leadership and oversight for external CDMOs, supporting manufacturing campaigns, tech transfers, troubleshooting, and investigations. Collaboration across Discovery, Analytical Chemistry, Quality, Regulatory CMC, and Clinical teams is essential, as is the ability to work effectively with external consultants and manufacturing partners.
Key Responsibilities
Education & Qualifications
Travel & Location
You will be expected to travel periodically, based on business needs, including attending Together Weeks, Together Days, and functional meetings as requested by the Company. This role is expected to be on-site an average of three days per week, unless otherwise requested.
Company Overview:
MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
EEO Statement:
MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at MBX Biosciences?
Help others prepare — share your experience anonymously.
BIOTECHNOLOGY
Hormone Analogues for Rare Endocrine Diseases
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo